Author
Listed:
- Yannic C. Bartsch
(Ragon Institute of MGH, MIT and Harvard)
- Stephanie Fischinger
(Ragon Institute of MGH, MIT and Harvard
Institut für HIV Forschung, Universität Duisburg-Essen)
- Sameed M. Siddiqui
(Computational and Systems Biology Program, Massachusetts Institute of Technology
Broad Institute of MIT and Harvard)
- Zhilin Chen
(Ragon Institute of MGH, MIT and Harvard)
- Jingyou Yu
(Ragon Institute of MGH, MIT and Harvard
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School)
- Makda Gebre
(Ragon Institute of MGH, MIT and Harvard
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School)
- Caroline Atyeo
(Ragon Institute of MGH, MIT and Harvard)
- Matthew J. Gorman
(Ragon Institute of MGH, MIT and Harvard)
- Alex Lee Zhu
(Ragon Institute of MGH, MIT and Harvard)
- Jaewon Kang
(Ragon Institute of MGH, MIT and Harvard)
- John S. Burke
(Ragon Institute of MGH, MIT and Harvard)
- Matthew Slein
(Ragon Institute of MGH, MIT and Harvard)
- Matthew J. Gluck
(Space Exploration Technologies Corp
Icahn School of Medicine at Mount Sinai)
- Samuel Beger
(Space Exploration Technologies Corp)
- Yiyuan Hu
(Space Exploration Technologies Corp)
- Justin Rhee
(Space Exploration Technologies Corp)
- Eric Petersen
(Space Exploration Technologies Corp)
- Benjamin Mormann
(Space Exploration Technologies Corp)
- Michael de St Aubin
(Harvard Humanitarian Initiative)
- Mohammad A. Hasdianda
(Brigham and Women’s Hospital)
- Guruprasad Jambaulikar
(Brigham and Women’s Hospital)
- Edward W. Boyer
(Brigham and Women’s Hospital)
- Pardis C. Sabeti
(Broad Institute of MIT and Harvard
Harvard T.H. Chan School of Public Health
Howard Hughes Medical Institute
Massachusetts Consortium on Pandemic Readiness)
- Dan H. Barouch
(Ragon Institute of MGH, MIT and Harvard
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
Massachusetts Consortium on Pandemic Readiness)
- Boris D. Julg
(Ragon Institute of MGH, MIT and Harvard)
- Elon R. Musk
(Space Exploration Technologies Corp)
- Anil S. Menon
(Space Exploration Technologies Corp)
- Douglas A. Lauffenburger
(Department of Biological Engineering, Massachusetts Institute of Technology)
- Eric J. Nilles
(Brigham and Women’s Hospital)
- Galit Alter
(Ragon Institute of MGH, MIT and Harvard
Massachusetts Consortium on Pandemic Readiness)
Abstract
Antibodies serve as biomarkers of infection, but if sustained can confer long-term immunity. Yet, for most clinically approved vaccines, binding antibody titers only serve as a surrogate of protection. Instead, the ability of vaccine induced antibodies to neutralize or mediate Fc-effector functions is mechanistically linked to protection. While evidence has begun to point to persisting antibody responses among SARS-CoV-2 infected individuals, cases of re-infection have begun to emerge, calling the protective nature of humoral immunity against this highly infectious pathogen into question. Using a community-based surveillance study, we aimed to define the relationship between titers and functional antibody activity to SARS-CoV-2 over time. Here we report significant heterogeneity, but limited decay, across antibody titers amongst 120 identified seroconverters, most of whom had asymptomatic infection. Notably, neutralization, Fc-function, and SARS-CoV-2 specific T cell responses were only observed in subjects that elicited RBD-specific antibody titers above a threshold. The findings point to a switch-like relationship between observed antibody titer and function, where a distinct threshold of activity—defined by the level of antibodies—is required to elicit vigorous humoral and cellular response. This response activity level may be essential for durable protection, potentially explaining why re-infections occur with SARS-CoV-2 and other common coronaviruses.
Suggested Citation
Yannic C. Bartsch & Stephanie Fischinger & Sameed M. Siddiqui & Zhilin Chen & Jingyou Yu & Makda Gebre & Caroline Atyeo & Matthew J. Gorman & Alex Lee Zhu & Jaewon Kang & John S. Burke & Matthew Slein, 2021.
"Discrete SARS-CoV-2 antibody titers track with functional humoral stability,"
Nature Communications, Nature, vol. 12(1), pages 1-8, December.
Handle:
RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-21336-8
DOI: 10.1038/s41467-021-21336-8
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-21336-8. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.